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Synopsis 
Modern anesthetic agents have allowed for the rapid expansion of ambulatory 
surgery and the continuously growing list of hand procedures performed in this 
setting. Nonetheless, adequate postoperative pain control remains a challenging 
problem for patients and surgeons alike.  In this article we review various strategy 
options currently employed to attain pain control for patients undergoing 
ambulatory hand procedures.  
 An effective post-operative analgesic strategy begins with intraoperative anesthesia 
since it has been shown this can affect the level and perception of pain after surgery. 
The choice of general anesthesia, peripheral regional block with moderate sedation 
or bier block with its recent resurface with the use of a more distal tourniquet 
placement and less anesthetic, and the most newly described wide-awake surgery 
that is becoming more popular, depends on patient characteristics, coexisting 
conditions, location and expected length of the specific procedure. Once the patient 
is on the PACU, the combination of intravenous and oral medication can dictate the 
length of stay in the hospital as well as the level of pain control achieved in the first 
hours after sedation wears off. However, maybe the most challenging component of 
the analgesic strategy is the selection of the right home medication regiment as 
overmedication can lead to significant side-effects such as nausea, vomiting, 
sedation, dizziness, respiratory depression and substance dependence significantly 
affecting patients function, whereas inadequate pain control increases patient 
morbidity and suffering and results in repeat emergency room visits and calls to the 
office. There are many categories of medications to choose from including mild 
analgesics such as acetaminophen, NSAID’s and the newer categories such as COX-2 
selective inhibitors and ketorolac, as well as opioids and combinations thereof. 
Active exploration of new categories with a focus on extended, complete and safe 
pain relief with minimal effort from the patient has led to more modern strategies 
such as Continuous Peripheral Nerve Blockade (CPNB) and innovative formulations 
that pack established anesthetic agents in extended release biocompatible vehicles 
such as Exparel that can provide effective analgesia for over 96 hours. These 
modern strategies, even though are in just their early stages have generated some 
very promising results and hold great promise in shaping the future of ambulatory 
hand surgery.  
 
Keywords:  Ambulatory Hand Surgery, Wide awake surgery, Combination 
analgesics, Nerve Block, Exparil 
 
Key Points (5):   
• The choice of intra-operative anesthesia and medication regiment in the 
PACU can have a great effect on hospital length of stay and recovery profile 
• Wide awake surgery can be used for 95% of hand procedures and 
circumvents the need for preoperative testing while decreasing need for 
narcotics  
• Newer Bier block modifications that include more distal tourniquet 
placement, allow for the use of less anesthetic making it a safer technique 
• There is a shift away from opioid analgesic montherapies to combination 
formulations with complimentary mechanisms that can achieve greater 
efficacy and safety profile 
• Exparil that s only approved for wound infiltration and can achieve 96 hours 
of analgesia is currently being investigated as a peripheral nerve block agent 
 
INTRODUCTION 
The exponential growth in medical technology and availability of better anesthetic 
agents, triggered a dramatic growth in ambulatory surgery over the last two 
decades. The rapid onset and termination of effect of modern anesthetic agents as 
well as better understanding of their mechanism of action, allowed longer cases to 
be performed on an ambulatory basis with quicker recovery of patients that can be 
discharged home more safely 1. As of 2003, 70% of the surgical procedures in North 
America were performed on ambulatory basis and it now accounts for the majority 
of surgery performed in USA, some European countries and Australia 1,2. 
Orthopaedic, and more particularly hand procedures, account for a large portion of 
these outpatient surgeries 3 and are likely only to increase with time as healthcare 
economic restrictions continue to influence the way we practice. Leblanc et al 4 
analyzed the cost and efficiency associated with performing carpal tunnel releases 
(CTR)  in the main operating room as compared to the ambulatory setting and found 
that the use of the main OR for CTR is almost four times as expensive, and less than 
half as efficient as when performed in an ambulatory setting.  
Even though expense and efficiency are important driving factors, perhaps the main 
prerequisite for performing ambulatory surgery is minimal postoperative pain that 
can be controlled with oral analgesics. With the ever-expanding boarders of what 
can be done as outpatient, pain control is something that still remains challenging 
for surgeons and patients alike 5. It is estimated that up to 30–40% of ambulatory 
surgical patients suffer from moderate to severe pain during the first 24–48 hours 
after their discharge 2, which often times will interfere with sleep and daily 
functioning. Even though this improves with time, postoperative pain remains the 
most common reason for recurrent general practitioner office visits and 
unanticipated hospital admission 6-8. This becomes especially important in hand 
patients. Chung et al 3 prospectively studied 1008 consecutive ambulatory surgical 
patients across 8 surgical specialties and found that in the PACU, orthopedic 
patients (that included hand procedures) had the highest incidence of pain, more so 
than urologic, general surgery and plastic surgery patients. Furthermore, in a survey 
by Rawal et al 7 that analyzed post-operative pain it was found that 37% of hand 
surgery patients will suffer from moderate to severe pain post-operatively, affecting 
their function and quality of life.  
Traditionally the patient’s pain is managed with general anesthesia and narcotic 
medication for surgery, followed by oral medications, including acetaminophen, 
non-steroidal anti-inflammatory drugs (NSAIDs), opioid-containing oral analgesics 
(e.g., codeine-acetaminophen), or a combination of these along with intravenous 
pain medications (including patient-controlled analgesia), after surgery 9. Despite 
the availability of these analgesic drugs, many patients still do not achieve effective 
pain control 10, often times because adverse gastrointestinal, hemostatic, and renal 
effects that become prohibitive to achieving adequate analgesic concentrations.  
 
INTRA-OPERATIVE ANALGESIA/ ANESTHESIA 
The choice of analgesia and anesthesia during the surgical procedure can have a 
great effect on the pain level and chance of successful pain control post-operatively 
and often dictates the length of stay of the patient in the hospital after the 
procedure.  
 
General anesthesia 
It has been known in the shoulder literature for quite some time 11 12, that regional, 
as opposed to general anesthesia can result in shorter recovery times and faster 
hospital discharge after surgery. Similarly, Chan et al 13 prospectively examined 
three anesthetic techniques during hand procedures, namely general anesthesia 
(GA) and two regional anesthetic techniques, IV regional anesthesia (IVRA) and 
axillary brachial plexus block, with respect to clinical outcome, time efficiency, and 
hospital cost. He found that regional anesthesia is associated with a more favorable 
patient recovery profile than GA, requiring less nursing care in the PACU and an 
earlier hospital discharge. These findings were re-demonstrated a few years later by 
McCartney et al 14 in a prospective randomized trial of 100 ambulatory hand surgery 
patients showing that single-shot axillary brachial plexus block significantly reduces 
pain in the immediate post-op period, reducing PACU times, total hospital time and 
increasing time to first analgesic request before discharge. However, when they 
tracked patient-reported pain beyond the immediate post-op period they found no 
difference in pain level on postoperative day 1 or up to 14 days after surgery when 
compared with GA. 
 
Peripheral Regional Blocks 
Single-injection plexus blocks are currently the most commonly used modality for 
regional anesthesia in upper-extremity surgery. First performed by the American 
surgeon William Stuart Halsted in 1885, it involves injecting a local anesthetic in the 
area of the brachial plexus which can provide analgesic effects from 12 to 24 hours 
15 16. Depending on the surgical area, this can be administered as an intrescalene, 
supraclvicular or infraclavicular block. The most common block is the interscalene 
block that affects the root-trunk level of the brachial plexus and can be used for 
procedures involving the shoulder, proximal aspect of the humerus, and distal 
aspect of the clavicle but is inadequate for procedures that are distal to the elbow. 
The supraclavicular block that affects the anterior and posterior divisions of the 
trunks of the brachial plexus, as well as the infraclavicular nerve block that targets 
the brachial plexus at the level of the cords before the exit of the axillary and 
musculocutaneous nerves is well suited for procedures involving the arm, elbow, 
forearm, and hand. Finally the suprascapular and axillary nerve blocks have a 
similar coverage with the interscalene block and can be an effective option for 
intraoperative and postoperative pain control for shoulder procedures. 
Overall peripheral nerve blocks can offer cost effective pain control for patients 
undergoing upper extremity procedures and have the potential to minimize need 
for narcotic use, shorten hospital stays and increase patient satisfaction 9. 
Nevertheless, a number of complications have been reported with the use of these 
blocks that include pneumothorax, recurrent laryngeal nerve blockade phrenic 
blockade, peripheral neuropathy, spinal cord damage and sympathetic chain 
blockade 17.  With the use of ultrasonographic guidance the safety of peripheral 
nerve blocks has been enhanced and allowed for the more accurate placement of the 
blocks with lower anesthetic volumes.  
 
Intravenous Regional Anesthesia (IVRA) 
Intravenous Regional Anesthesia (more readily know as the Bier block) was first 
developed by Dr. August Bier in 1908, and still remains an effective regional 
anesthesia technique frequently used for upper extremity surgery. It generally 
involves placement of a tourniquet above the elbow, exsanguination of the 
extremity with an esmarch and tourniquet inflation to ensure arterial occlusion 
followed by slow injection of an anaesthetic agent (typically Lidocaine) into the iv 
cannula of the surgical hand 18.  
This technique is intended to provide a bloodless field with rapid onset, high 
reliability complete anesthesia, eliminating the need for general anesthesia while 
leaving local tissue or anatomic structures undistorted 19. However, this technique is 
often associated with tourniquet pain and in many cases the patient still requires 
sedation 20 which is associated with all the well-described side effects of nausea, 
vomiting and decreased cognitive function. These side effects, along with failure to 
provide adequate postoperative analgesia 21 ultimately impacts time to discharge. In 
an effort to improve the quality of the block, over the years various adjuvants have 
been added to the local anesthetic solution including opioids, non-steroidal anti-
inflammatory drugs, [alpha]2-adrenergic agonists, sodium bicarbonate, and muscle 
relaxants 21 with varying degrees of success. 
 
Another concern associated with the Bier block is its potential to cause both local 
and systemic pharmacologic toxicity as the tourniquet is deflated and various 
serious complications and death have been reported in the literature 
{Reynolds:1984tm}. Guay et al 22 recently performed a systematic review of the 
adverse events associated with intravenous regional anesthesia (Bier block) and 
describes cases of local anesthetic toxicity, seizures, compartment syndrome, 
cardiac arrests and deaths. Interestingly seizures have been reported even with 
lidocaine at its lowest effective dose (1.5 mg/kg). He concluded that even though 
serious complications might result from the utilization of the Bier block, their 
incidence is relatively low and therefore this technique can be considered a safe 
method of providing anesthesia during surgery. To minimize these risks, 
precautionary measures have been described when using this technique.  To reduce 
the bolus effect of the anesthetic agent as it is released into the general circulation 
19, cyclical release of the tourniquet is most times necessary. Additionally, a 
minimum tourniquet time of 30 minutes is required when using a Bier block 23 
ensuring enough diffusion of the total anesthetic agent before allowing its systemic 
distribution.  This limitation makes the use of the Bier block impractical for short 
procedures such as carpal tunnel releases etc further narrowing its indications in 
outpatient hand procedures.  
In recent years there has been a revived interest in the reviving and enhancement of 
the Bier block. Investigators have described modifications to the Bier technique 
such as placing the tourniquet distal to the elbow while reducing the amount of 
lidocaine used to achieve adequate anesthesia. Arslanian et al 23 describe their 
experience with forearm Bier block in 121 procedures performed and interviewed 
by telephone 24 hours postoperatively. They report that all patients received 
adequate anesthesia from the block with no intraoperative or postoperative 
complications. They were also able to reduce tourniquet time to about 10.1 minutes 
using this technique. 
Another area of adjustment, has been in the choice of anesthetic agent. 
Meprivacaine, prilocaine, and bupivacaine 24 or use of adjunctive analgesics such as 
ketorolac and combinations thereof 25 have been described in the literature to 
provide varying durations of action and blockade. Opioids including morphine 26 
,fentanyl 27 sufentanil, and meperidine have been added to the IVRA solution with 
contradictory results 28. Invariably, regardless of the mixture used one important 
disadvantage of this technique remains the rapid onset of pain at the operative site 
after the tourniquet has been deflated {Ceremuga:1998to}.  Nonetheless, lidocaine, 
which is typically given as 0.5% plain lidocaine at a maximum dosage of 3 mg/kg, 
still remains one of the more common anesthetics used for the Boer block due to its 
low potential for systemic toxicity.  
 
Wide awake surgery 
Wide-awake hand surgery (WAHS) was first introduced by Lalonde in 2007 29 and it 
involves the use of local anaesthetic with adrenaline or epinephrine directly into the 
surgical field. Epinephrine is a potent vasoconstrictor, which decreases the bleeding 
in the surgical field thus avoiding the need for a tourniquet that is known to cause 
considerable discomfort. This idea became possible after the emergence of recent 
evidence suggesting that it is safe to inject epinephrine (adrenaline) in the human 
finger, once thought to lead to digital ischemia and necrosis 30-32.  Lidocane provides 
local anesthesia allowing patients to remain comfortable through simple operations 
such as CTR or Dupytrens as well as more complex surgeries such as arthroplasties 
33 and tendon transfers circumventing the need for regional anesthesia, general 
anesthesia and sedation and hence all the risks associated with these.  In fact, 
Lalonde et al 34 claims that this approach can be used for up to 95% of all hand 
surgery procedures. In a recent article in the Journal of Hand Surgery 35, he 
describes the ideal dosage and location for placement of the injection for various 
procedures and serves as a good resource and guide for  hand surgeons. Further 
advantages of WAHS, include significant savings in cost and since no anesthesia is 
administered it eliminates pre-assessment visits, and pre-operative investigations 
36-39 . Bypassing pre-operative testing opens up the possibility for patients with 
significant comorbidities that would otherwise be denied surgery due to the risk of 
anesthesia, to safely undergo hand procedures. An added benefit is that since 
patients are awake during the procedures, they can receive education about their 
surgery and post-operative management but can also participate by actively flexing 
and extending the digits so the surgeon can evaluate, for example, whether a tendon 
repair fits through the pulleys intra-operatively.   
Elimination of anesthesia also means that patients can practically get up after 
surgery and go home with no need for extensive PACU care, medication 
administration and the associated side effects such as drowsiness, nausea or 
vomiting. In a prospective cohort study by Davison et al 40 that compared 100 
consecutive CTRs done with only lidocaine and epinephrine to 100 consecutive 
CTRs done with IV sedation, they found that 93% of the patients in either group 
would choose the same method of anesthesia they received again demonstrating 
that people would choose the method that they are more familiar with. More 
importantly they found that wide-awake patients spent less time at the hospital 
than sedated patients (2.6 hrs vs 4.0 hrs) and that only 3% of wide awake patients 
required preoperative testing (blood work, electrocardiograms, and/or chest 
radiographs) as compared to 48 % of sedated patients. Additionally, preoperative 
anxiety levels for wide-awake patients were lower than for sedated patients even 
though postoperative anxiety was similar. Narcotics were used by only 5% of 
unsedated patients as opposed to 67 % of sedated patients despite reported 
adequate pain control by 89 % and 90 % of patients, respectively. Surprisingly, post-
operative nausea and vomiting (PONV) incidence was very low for both groups in 
this study (1% and 7%) unlike most other previous studies 41 that demonstrate 
higher incidence of PONV in patients that receive sedational anesthetic causing 
unplanned admissions and greater dissatisfaction.  
 
POST-OPERATIVE ANALGESIA  
PACU 
Effective pain management in the PACU can have a big impact on patient 
satisfaction, time to discharge and their post-operative course once they go home. 
Morphine and fentanyl are widely used in ambulatory patients to provide analgesia 
during Phase I recovery. Fentanyl has been advocated due to it’s a faster onset time 
and therefore the more rapid control of pain, potentially avoiding total opioid dose 
and related side effects. Claxton et al 42 compared the use of intravenous morphine 
and fentanyl after painful ambulatory procedures in a prospective randomized trial 
and demonstrated that morphine produced a better quality of analgesia but was 
associated with an increased incidence of nausea and vomiting, the majority of 
which occurred after discharge. They concluded that the reduced side effects in 
combination with a short duration of action of fentanyl may facilitate earlier 
discharge and produce fewer complications after discharge. 
 
Home Analgesia 
Oral analgesia is the mainstay of pain control once the patient leaves the hospital. 
Medications prescribed should allow the patient to perform normal activities of 
daily living, produce minimal side-effects, not interfere with the healing process and 
be easy to manage by the patient. Depending on the type of procedure performed, 
breakthrough medications might also be indicated to keep pain under control in 
case that the prescribed analgesic is ineffective. Postoperative pain after ambulatory 
hand surgery is typically managed with a combination of oral medications including 
acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), opioid-containing 
oral analgesics (e.g., codeine-acetaminophen). Regardless of the choice of 
medication, patient education on what to expect, ways to manage pain and how to 
use the medications prescribed, remains paramount.  
 
Acetamenophen 
Acetamenophen (or paracetamol) is one of the most widely used analgesics 
worldwide. It is effective, safe, cheap with a favorable adverse effect profile 43. Yet, 
its mechanism of action is poorly understood. There is some evidence that it has a 
central antinociceptive effect and some of the proposed mechanism of action 
include inhibition of COX-2 in CNS or inhibition of putative central cyclooxygenase 
‘‘COX-3’’  44, 45. There is also some evidence that it modulates inhibitory serotonergic 
pathways and may also prevent prostaglandin production at the cellular level. It is 
known that unlike NSAIDs, it does not irritate gastric mucosa, affect platelet 
function or cause renal insufficiency making it a very versatile medication.  
 
NSAIDs 
Prostaglandins, and their role in pain modulation, were first discovered in the 
1960s.  Shortly after, in 1965, Sir John Vane first demonstrated the in vivo reduction 
in prostaglandin levels by inhibition of prostaglandin synthetase, now known as 
cyclooxygenase (COX) 46. Once this enzyme was identified, the nonsteroidal anti-
inflammatory drugs (NSAIDs), were developed to inhibit it. Even though some 
central action has been reported 47, the generally accepted mechanism of action of 
NSAIDs today, remains the attenuation of prostaglandin synthesis by inhibition of 
cyclooxygenase (COX) enzymes 48. 
NSAIDs are now part of most day surgery pain regimens. Their anti-inflammatory 
properties not only provide pain relief but may help reduce local edema and 
minimize the use of more potent drugs. The 1998 guidelines for the use of NSAIDs in 
the perioperative period, issued by the Royal College of Anaesthetists, stated that 
based on the strongest evidence available, ‘‘in situations where there are no 
contraindications NSAIDs are the drug of choice after many day-case procedures’’ 7. 
Today is estimated that 20-30% of Americans use an NSAID each year, and 1-2% 
use NSAIDs every day 49.  
Despite their success, one of the main concerns with the use of NSAID remains their 
gastrointestinal toxicity, which led to the exploration of ways to reduce their side-
effect profile.  The two COX isoenzymes were discovered in the late 1980s, with 
COX-1 largely involved in homeostasis, including the maintenance of 
gastroprotective mechanisms and renal blood flow; and COX-2, which is upregulated 
during the inflammatory response. COX-2-selective drugs emerged shortly after 
which the World Health Organization has categorized as a new subclass of NSAIDs 
(coxibs). Despite continuing controversy over the safety of the coxibs and concerns 
of a higher risk of myocardial infarction there appears to be no clear differences in 
the cardiovascular risks of the currently available coxibs and the non-selective 
NSAIDs when used at the recommended doses 46. On the other hand, even with a 
favorable side-effect profile, they perform equally as well as the ns-NSAIDs. In a 
recent systematic review by Romsing et al 50, they showed that Rofecoxib 50 mg and 
parecoxib 40 mg have an equipotent analgesic efficacy relative to traditional NSAIDs 
in post-operative pain after minor and major surgical procedures.  
 
Ketorolac 
Ketorolac is a newer nonsteroidal anti-inflammatory drug (NSAID) analgesic, 
considered a central nervous system agent 51, that was first approved for  use by the 
U.S. Food and Drug Administration in 1997. Similar to classic NSAID’s, when co-
administered with an opioid, it exhibits marked opioid-sparing effects, allowing a 
25% to 50% reduction in opioid requirement 51. A randomized double-blinded 
study by Kinsella et al 52, demonstrated that morphine requirements were 3 times 
less in the first 24hrs in patients having major orthopedic procedures who had 
adjuvant ketorolac administered during the postoperative period.  
 
Since it acts by inhibiting the cyclooxygenase pathway it is therefore also a potent 
inhibitor of platelet aggregation and some concerns were raised with its use in the 
perioperative period. Even though there is a paucity of literature in the use of 
ketorolac with hand procedures in particular, it has been looked at in the spine 
literature where Chin et al. 53 found no risk of bleeding complications compared 
with that of their control group in patients having microdiscectomy after a single 
intraoperative dose of ketorolac. 
  
For all NSAIDs, careful patient selection is important. Specifically, a history of 
coronary artery disease, gastrointestinal risk factors such as gastric ulcers and renal 
insufficiency has to be taken into consideration before prescribing ns-NSAIDs, C OX-
2 selective inhibitors or ketorolac. After weighing the risks and benefits, NSAID’s, 
when used at the right dosing, remain one of the most effective analgesics and anti-
inflammatory medications that can safely be used for post-operative analgesia after 
hand procedures.  
 
Opioids 
Even though opioids are commonly used in ambulatory surgery procedures in the 
USA, their role is sometimes questioned because of their well known side effects of 
nausea, vomiting, sedation, dizziness, respiratory depression and substance 
dependence 54. Weak opioids such as codeine and tramadol are commonly used and 
are often times prescribed in combination with acetaminophen. In a controlled trial 
55, postoperative pain management at home using either tramadol, metamizol, or 
paracetamol as single substances after ambulatory hand surgery has been shown to 
be inadequate for up to 40% of all patients. Consequently, there has been an 
increasing focus on combining analgesic medications with different mechanisms of 
actions and complementary pharmacokinetic profiles in hopes to not only achieve 
greater efficacy but also a better safety profile  56. For example in a randomized, 
double-blind, multicenter trial comparing the efficacy and safety of tramadol HCL 
37.5 mg/paracetamol 325 mg combination tablet with tramadol HCL 50 mg capsule 
in the treatment of postoperative pain following ambulatory hand surgery it was 
found that analgesic efficacy of the two treatments was comparable but multiple-
dose tramadol/paracetamol treatment showed a better safety profile than tramadol 
monotherapy 57.  
 
FUTURE DIRECTIONS 
Extended, complete and safe pain relief without the need for oral medication and 
minimal effort from the patient are the desired characteristics of an ideal analgesic 
strategy/ system. Oral or intravenous analgesics are by definition systemic 
medications and invariably associated with side-effects. One also has to consider 
possible medication interactions, use of concurrent anticoagulation and any pre-
existing conditions or comorbidities as these can affect the clearance and effective 
dosing of the analgesic used.  A local or peripheral analgesic strategy circumvents 
(or at least minimizes) the need for systemic medications and can potentially not 
only prevent the associated side-effects as well as potential medication interactions 
but also relies less on patient compliance and requires less customization from 
patient to patient.  
 
Continuous Peripheral Nerve Blockade (CPNB)  
This strategy for post-operative analgesia entails the percutaneous insertion of 
perineural catheters close to the peripheral nerve of interest and the continues 
infusion of local anesthetic to achieve blockade in its corresponding distribution.  
Richman et al 54, conducted a meta-analysis of randomized controlled studies  
comparing the effectiveness of CPNB and opioids. He identified 19 studies (12 of 
which for upper extremity procedures) including more than 600 patients and 
revealed that CPNB provided better postoperative analgesia compared with opioids 
at 24 h, 48 h and 72 hrs post-operatively. Furthermore, significant reduction in 
opioid use (when used as a rescue medication) was noted in patients receiving 
perineural analgesia with fewer opioid-related side effects. 
However, variable success rates of CNPB have been reported in the literature. In a 
single-center, prospective, double-blind, randomized and placebo-controlled study, 
Goebel et al 58 comparing single-shot and CPNB by insertion of an patient-controlled 
interscalene catheter that contained either 0.2% ropivacaine (catheter group) or 
normal saline solution (single-shot group)  after major open-shoulder surgeries. 
They showed that there was significantly less consumption of rescue medication in 
the catheter group, but only within the first 24 h after surgery; opioid use past day 1 
was equal in the 2 groups and incidence of side effects did not differ between the 
two groups. 
Catheter patency or secondary catheter block has been identified in many studies as 
a major mode of failure of CPNB with rates ranging from 10%-20% 59-61.  Event 
though most studies have been limited by small patient samples one of the largest 
studies published comes from the hand literature by Ahsan et al 62 that 
retrospectively explored the incidence of failure in 207 patients that received 
infraclavicular or  supraclavicular CPNB for postoperative analgesia after upper 
extremity procedures. In their series, CPNB failure rate for infraclavicular and 
supraclavicular catheters was 19% and 26%, respectively. Other mechanisms of 
CNPB failure that have been reported and could explain these results include 
catheter migration 63, fluid leakage at the catheter site 59 and dislodgement or 
obstruction of the tubing 64. Incorrect catheter placement 65, despite the significant 
increase in placement accuracy with the use of ultrasound guidance, also still 
remains an issue.  
In addition to the failures associated with the pump, catheter and block placement, 
CPNB use is not innocuous.  Serious complications have been reported such as peri-
catheter hematoma formation and intravascular puncture 66, myonecrosis, systemic 
or local anesthetic toxicity
 
and prolonged Horner syndrome 67. 
 
The presence of a 
catheter that violates the skin also raises the concern for introduction of bacteria to 
the area, and infection rates after catheter placement has been reported to be 0%-
3% 68.  
 Furthermore, their satisfactory function relies on the patient to take care of the 
pump at home. In order to implement these systems in the ambulatory setting, one 
must assure that the patient’s are very well educated on how to care for them and 
make sure there is a very stringent follow up system in place. 
 
DepoFoam (Exparil) 
Multiple attempts have been made to extend the effect of local anesthetics and 
blocks to attain longer local regional anesthesia in the early post operative period 
decreasing the need for oral systemic narcotics and non-opioid analgesics, such as 
NSAIDs. Despite multiple efforts and approaches with the use of adjuvants, vehicles 
and gel formulations of classic analgesics and anesthetics the typical duration of 
adequate pain control has been a maximum of 24 hrs.  
DepoFoam® bupivacaine (Pacira Pharmaceuticals, Inc., San Diego, CA, USA) or more 
widely known as Exparel, is a novel extended-release liposomal bupivacaine-based 
analgesic. It was granted FDA approval in 2011 and is indicated for postsurgical 
analgesia, designed for single-dose local administration into the surgical wound 69. 
The extended-release formulation consists of microscopic, spherical, lipid-based 
which allows for diffusion of bupivacaine over an extended period, resulting in pain 
relief for up to 96 hours after surgery. This is in contrast to infiltration with classic 
local anesthetic agents (eg, bupivacaine HCl, ropivacaine) that are widely used today 
resulting in analgesia that is generally limited to about 8 hours or less. 
In a recent randomized, multicenter, double-blind phase 3 clinical study 70, Exparel 
was compared with placebo for the prevention of pain after bunionectomy. Using a 
numeric rating scale (NRS) for pain, scores were significantly less in patients treated 
with DepoFoam bupivacaine as compared to patients receiving placebo at 24 hours 
and 36 hours. They also found that more patients in the Exparel group avoided use 
of opioid rescue medication during the first 24 hours and were pain-free up to 48 
hours after surgery. Moreover, fewer adverse events were reported by patients 
treated with DepoFoam bupivacaine (59.8%), versus placebo (67.7%). Portillo et al 
71 just completed their systematic review of prospective studies on the use of 
DepoFoam and  the analysis of the incidence reported adverse effects when 
compared to conventional bupivacaine or placebo. They looked at DepoFoam use in 
knee arthroplasty, hemmorrhidectomy, augmentation mammoplasty, bunionectomy 
and healthy volunteers. They found that DepoFoam bupivacaine used in therapeutic 
doses was well-tolerated, and showed a favorable safety profile compared to 
bupivacaine and controls.  
To the best of our knowledge, no studies have been conducted to date that explore 
the use of exparil specifically in hand surgery. Such studies are needed to validate 
the use of this promising technology in our patients.  
 
Extended Peripheral Nerve Blocks 
Currently available local anesthetics approved for single-injection peripheral nerve 
blocks have a maximum duration of <24 hours. Just as in the case of extended local 
anesthesia, attempts have been made to prolong the duration of peripheral nerve 
blocks with the use of various vehicles such surgically implantable pellets 72, 
hyaluronic acid matrices 73 or lipid-protein-sugar particles 74 just to name a few. 
However, clinical translation and wide adoption of such systems of sustained 
release formulations for local anesthetics has mostly been limited by adverse tissue 
reaction with reports of myotoxicity, inflammation, and neurotoxicity. 
Exparil, which is known to release for at least 96 hours after injection, is currently 
FDA-approved exclusively for wound infiltration but not peripheral nerve blocks 75. 
Some information of the use of Exparel in nerve block fashion however, has started 
to emerge in recent years. In the field of plastic surgery, Morales et al 76 reports their 
experience with 64 female patients who received liposomal bupivicaine injections in 
an abdominal field block fashion for abdominoplasty with rectus plication. Based on 
their postoperative data and questionnaires, these patients experienced reduced 
postoperative pain, required less postoperative narcotic medication, and resumed 
both earlier ambulation and normal activity. Furthermore, Ilfeld et al 75 
administered bilateral single-injection liposomal bupivacaine femoral nerve blocks 
in 14 healthy volunteers. Using the maximum voluntary isometric contraction of the 
quadriceps femoris muscle and tolerance to cutaneous electrical current in the 
femoral nerve distribution as end points, they report partial sensory and motor 
block of >24 hours. 
 
Exparil’s biocompatibility near nerve tissue is not well characterized but a few 
studies have began to look at the safety in such scenarios. McAlvin et al 77 injected 
Exparel close to the sciatic nerves in rats and compared its effects to that of different 
concentrations of bupivacaine HCl. They found that even though Exparel injection 
caused a longer sciatic nerve blockade, median inflammation scores determined by 
histologic sections four days after injection, were slightly higher. However, 
myotoxicity in all groups was not statistically significantly different and no 
neurotoxicity was detected in any group. 
Richard et al 78, performed single-dose toxicology studies of 3 doses of Exparil (9, 
18, and 30mg/kg), and compared them to bupivacaine solution (9 mg/kg) and 
saline. When these were injected around the brachial plexus nerve bundle of rabbits 
and dogs, they found that at the same dose, Exparel resulted in a 4-fold lower 
maximum plasma concentration of bupivacaine and was well tolerated at all doses. 
Histopathology evaluation on Day 3 and 15, only revealed minimal to mild 
granulomatous inflammation of adipose tissue around nerve roots and concluded 
that it did not produce any nerve damage in their model.  
Exparel continues to be actively investigated for postsurgical analgesia via 
peripheral nerve block 78 and so far 2 phase 1 studies have been completed and, 
based on the safety data, the FDA has now approved subsequent phase 2 and 3 
trials. If this, along with other newer analgesics continue to prove safe and 
efficacious, we may soon be able to provide long lasting pain relief to patients 
undergoing ambulatory hand procedures, without the use of oral medications and 
hence without their well described side-effects.  
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